Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2007

View Archived Issues

AMG-386/chemotherapy combination shows promise in cancer patients

Survival improved with ZD-4054 in prostate cancer patients with bone metastases

Esophageal tumor regression seen with NY-ESO-1 protein vaccine

Preclinical data on MOR-202, a fully human anti-CD38 MAb for the treatment of MM and leukemias

Shareholder approval sought in meeting for Peptech name change

Akesis seeks FDA approval to commence phase IIa evaluation of AKP-020 for type 2 diabetes

Jerini submits NDA for icatibant as HAE treatment

Peplin reports interim analysis of topical gel for AK

Camptothecin-incorporating micelles effective in stroma-rich pancreatic cancer

A novel KSP inhibitor by Merck & Co. shows activity in vivo

New agents for treating gastrointestinal disorders reported in recent patents

Novel diagnostic agents imparted in recent GE and Fujifilm patents

Recent Astellas patent discloses new therapeutic agents for benign prostatic hypertrophy

Phase III trial for low-dose formulation of Zenvia approved under SPA

Accentia nears IND submission for Revimmune

Horizon initiates follow-on phase III study of NSAID

Apatone successfully completes first clinical trial for treatment of cancer

Anacor Pharmaceuticals and GlaxoSmithKline to collaborate on boron-based therapeutics

New synthetic natriuretic peptide with in vivo activity for the treatment of heart failure

Cyclacel to acquire Align

Bind Biosciences awarded phase I SBIR grant for HRPC research

Improved lipid profile and insulin sensitivity by MBX-213, a novel dual PPARalpha/gamma agonist

Patient dosing begins in Jerini Ophthalmic phase I trial for age-related AMD

Living Cell Technologies reports promising initial data from DiabeCell phase I/II trial

Biothera commences I/II trial of Imprime PGG and MAb in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...